Oropharyngeal Cancer Clinical Trial
Official title:
A Phase II Study of Transoral Robotic Surgery With Adjuvant Therapy for Surgically Resectable HPV-positive Oropharyngeal Cancer
Standard-of-care treatment options for oropharyngeal cancer often result in long-term side
effects that interfere with normal quality of life. A minimally-invasive transoral robotic
surgery (TORS) approach has been developed to operate on the disease site while affecting the
surrounding tissue as little as possible. Researchers think that this approach may help to
control the disease and avoid such long-term side effects.
The goal of this clinical research study is to learn if minimally-invasive transoral robotic
surgery (TORS) can help to control HPV-positive oropharyngeal cancer. Transoral means through
the mouth. The TORS approach is called the Intuitive Surgical da Vinci Surgical System.
Researchers also want to learn if this surgery affects participants' ability to speak and
swallow.
Study Surgery:
If you are found to be eligible to take part in this study, you will be scheduled for
surgery. You will receive general anesthesia to make you sleep during the procedure. You will
be asked to sign a separate consent form that describes the anesthesia and its risks. If the
doctor thinks it is needed, the abnormal area will be looked at with a tube that has a
lighted camera on one end (called a laryngoscopy) to check the size of the tumor and to look
for any additional cancerous areas.
The tumor will be exposed with standard equipment after the teeth are protected with a dental
guard. Using the robotic surgical system, the tumor will be removed.
Your affected lymph nodes will be surgically removed through your neck. The robotic system
will not be used for that part of the surgery. The nerve that controls the shoulder, the
blood vessel that brings blood back to the heart from the brain and neck, and the major
muscle of the front of the neck will all be saved, unless the tumor in the lymph nodes has
grown directly into those areas. A drain will be placed before the surgical wound is closed.
The drain will usually be removed within a week after surgery.
Based on the results of surgery, you will receive adjuvant therapy (therapy after the
surgery). For example, if your surgery does not remove enough of the cancer, you will be
referred to receive radiation therapy. There will likely need to be a 1-2 week delay before
you can receive radiation therapy. Your doctor will discuss this therapy with you in more
detail, including the risks.
Length of Study:
The surgery will be stopped if the doctor thinks the tumor is too large to be removed with
the robotic system. You will be taken off study if you are unable to follow study directions.
Your participation on the study will be over after the follow-up visits and data collection.
Follow-Up Visits:
Within 1-4 weeks after surgery (+/- 3 days):
- You will have a physical exam, including a cranial nerve exam of your tongue, palate,
and facial nerves.
- You will have an MBS.
- You will meet with a speech pathologist.
- You will complete the questionnaires about your speech and swallowing function.
At 6 months (+/- 2 months), 12 months (+/- 2 months), and 24 months (+/- 6 months) after
surgery:
- You will have an MBS.
- You will have a cranial nerve exam of your tongue, palate, and facial nerves.
- You will meet with a speech pathologist.
- You will complete the questionnaires about your speech and swallowing function.
As often as the doctor thinks it is needed for up to 5 years after surgery, the study staff
will check your medical record to find out how you are doing and about any treatments and
follow-up you have had.
This is an investigational study. The robotic surgical procedure (the daVinci Surgical
System) is FDA approved and commercially available. The study doctor can explain how the
surgery is designed to work.
Up to 150 participants will be enrolled in this study. All will be enrolled at MD Anderson.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03656133 -
Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy for HPV + Oropharyngeal Cancers
|
N/A | |
Withdrawn |
NCT01767961 -
Modified Barium Swallow in Measuring Swallowing Function After Surgery in Patients With Oropharyngeal Cancer
|
N/A | |
Completed |
NCT01695122 -
Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT01435252 -
A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab
|
Phase 2 | |
Recruiting |
NCT04708470 -
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00951470 -
Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema
|
N/A | |
Completed |
NCT01358097 -
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
|
N/A | |
Completed |
NCT00964977 -
Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis.
|
Phase 3 | |
Completed |
NCT01342978 -
Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time
|
N/A | |
Recruiting |
NCT05363709 -
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
|
Phase 2 | |
Completed |
NCT02280811 -
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
|
Phase 2 | |
Active, not recruiting |
NCT03777384 -
EValuating the Safety Of De-escaLated Head and Neck Irradiation in HPV positivE Oropharynx Cancer in Non-smokers/Minimal Smokers
|
||
Active, not recruiting |
NCT03729518 -
TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck
|
N/A | |
Recruiting |
NCT06121102 -
Standard Pulsed Radiofrequency Versus Supervoltage Pulsed Radiofrequency Glossopharyngeal Nerve in Oropharyngeal Cancer Pain
|
N/A | |
Recruiting |
NCT02984410 -
Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma
|
N/A | |
Recruiting |
NCT02960724 -
uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer
|
Phase 2 | |
Completed |
NCT02934724 -
Impact of HPV Vaccine On The Prevalence Of HPV In Norway
|
||
Withdrawn |
NCT00928161 -
Reflux Disease in Head and Neck Cancer Patients Undergoing Radiation Therapy
|
N/A | |
Recruiting |
NCT02012699 -
Integrated Cancer Repository for Cancer Research
|
||
Terminated |
NCT03555721 -
CytID Analysis of Oral Lesions
|